Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

elotuzumab

- PMLiVE

Onyx rejects $10bn takeover bid from Amgen

Says offer is too low, but doesn't rule out a deal

- PMLiVE

EMA commits to disclosure of data from trials

Seeks feedback on clinical trial data access policy

- PMLiVE

BMS appoints Dinesh Paliwal to board

He is CEO of audio firm Harman International

- PMLiVE

Setback for AZ and BMS as Onglyza flunks cardiovascular trial

Diabetes drug fails to show benefit over placebo

PatientsLikeMe signs clinical trial deal with inVentiv Health

Online patient network aims to help the CRO accelerate trial recruitment

- PMLiVE

Elotuzumab on track for multiple myeloma

BMS and AbbVie present phase II results at European Haematology Association meeting

- PMLiVE

BMS partners with Simcere to market arthritis drug Orencia SC in China

Builds on existing cancer/ cholesterol alliance between pharma companies

- PMLiVE

FDA clears Amgen’s Xgeva for rare bone condition

US approval provides alternative to surgery for use in giant cell tumour of the bone

- PMLiVE

Electronic medical records ‘could boost clinical trial efficiency’

Quicker recruitment times and lower development costs among potential benefits, says Parexel

- PMLiVE

GSK fires senior Chinese scientist over data fabrication

Pharma company dismisses head of Chinese R&D unit after tip-off about inaccurate MS data in journal

- PMLiVE

Ben Goldacre: No escape from trial transparency

Bad Pharma author says AllTrials and new European legislation make data disclosure unavoidable

- PMLiVE

Celgene’s Revlimid wins US lymphoma approval

FDA recommends extra indication for blockbuster cancer drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links